Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Precision Oncology market is set for strong growth through 2035, fueled by genomic advances, rising cancer cases, and increased use of targeted therapies.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North ...

Denmark: Zealand Pharma A/S, a biotechnology company focused on the discovery and development of peptide-based medicines, has ...

Zealand Pharma A/S (($DK:ZEAL)) has held its Q1 earnings call. Read on for the main highlights of the call. Zealand Pharma’s recent earnings call ...